Cover Image
Market Research Report

Global Fallopian Tube Cancer Therapeutics Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 905962
Published Content info 136 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Fallopian Tube Cancer Therapeutics Market 2019-2023
Published: August 1, 2019 Content info: 136 Pages
Description

About this market

Fallopian tube cancer is a less common type of gynecologic cancer and accounts for approximately 1%-2% of all gynecologic cancer cases. Technavio's fallopian tube cancer therapeutics market analysis considers sales from both targeted therapy and chemotherapy. Our analysis also considers the sales of fallopian tube cancer therapeutics in APAC, Europe, North America, South America, and MEA. In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as heavy research on targeted therapies, high efficacy of the same will play a significant role in the targeted therapy segment to maintain its market position. Also, our global fallopian tube cancer therapeutics market report also looks at factors such as growing attention toward women's health, an array of strong drug approvals, strategic alliance. However, difficulty in diagnosis, the strong threat from substitutes, high cost of treatment may hamper the growth of the fallopian tube cancer therapeutics industry over the forecast period.

Overview

Array of strong drug approvals

One of the major growth factors of the global fallopian tube cancer therapeutics market is the increasing number of drug approvals in recent years. Various pharmaceutical vendors started conducting research on novel targeted therapies. These targeted therapies have an affinity toward inhibiting the overexpression of a specific target and increasing the immunity of the body toward cancerous cells. The market also witnesses the presence of various other targeted therapies in the late stages of the pipeline for the treatment of fallopian tube cancer. Two of the heavily researched targeted therapies for the indication are PD-1 inhibitors and PD-L1 inhibitors. The studies conducted in the early stages of clinical trials for fallopian tube cancer suggest that these drugs show a significant reduction in the tumor while providing long-term relief. Such factors will lead to the expansion of the global fallopian tube cancer therapeutics market at a CAGR of over 8% during the forecast period.

Use of nanotechnology for effective treatment

Various researchers are conducting studies on developing a nanoparticle-based drug delivery system, which could help the drug in reaching the target site without reducing its bioavailability. They increase the half-life of the drug in the circulatory system and have the ability to bypass the barriers caused by the blood tissue, specific target tissues, and cells. They increase the onset of the drug while providing a prolonged therapeutic action. These factors help nanoparticles to be an effective drug delivery for the administration of chemotherapy drugs. as it helps in overcoming drug resistance mechanisms in various tumors while enhancing the drug penetration into the tumor. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global fallopian tube cancer therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global fallopian tube cancer therapeutics market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading fallopian tube cancer therapeutics manufacturers, that include AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, and Pfizer Inc.

Also, the fallopian tube cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Table of Contents
Product Code: IRTNTR31819

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Growing research on regenerative therapies
  • Advent of treatment vaccines for cancer
  • Use of nanotechnology for effective treatment

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Global fallopian tube cancer therapeutics market: Overview
  • Exhibit 19: Global fallopian tube cancer therapeutics market: Snapshot
  • Exhibit 20: Product - Market share 2018-2023 (%)
  • Exhibit 21: Comparison by product
  • Exhibit 22: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: VEGF inhibitors share in targeted therapy 2018-2023
  • Exhibit 24: PARP inhibitors share in targeted therapy 2018-2023
  • Exhibit 25: Other inhibitors share in targeted therapy 2018-2023
  • Exhibit 26: Targeted therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Chemotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Market opportunity by product
  • Exhibit 30: Customer landscape
  • Exhibit 31: Market share by geography 2018-2023 (%)
  • Exhibit 32: Geographic comparison
  • Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in North America
  • Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Europe
  • Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in Asia
  • Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 44: Top 3 countries in ROW
  • Exhibit 45: Key leading countries
  • Exhibit 46: Market opportunity
  • Exhibit 47: Impact of drivers and challenges
  • Exhibit 48: Vendor landscape
  • Exhibit 49: Landscape disruption
  • Exhibit 50: Vendors covered
  • Exhibit 51: Vendor classification
  • Exhibit 52: Market positioning of vendors
  • Exhibit 53: AstraZeneca Plc - Vendor overview
  • Exhibit 54: AstraZeneca Plc - Business segments
  • Exhibit 55: AstraZeneca Plc - Organizational developments
  • Exhibit 56: AstraZeneca Plc - Geographic focus
  • Exhibit 57: AstraZeneca Plc - Key offerings
  • Exhibit 58: AstraZeneca Plc - Key customers
  • Exhibit 59: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 60: Bristol-Myers Squibb Co. - Business segments
  • Exhibit 61: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 62: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 63: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 64: Bristol-Myers Squibb Co. - Key customers
  • Exhibit 65: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 66: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 67: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 68: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 69: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 70: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 71: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 72: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 73: GlaxoSmithKline Plc - Business segments
  • Exhibit 74: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 75: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 76: GlaxoSmithKline Plc - Segment focus
  • Exhibit 77: GlaxoSmithKline Plc - Key offerings
  • Exhibit 78: GlaxoSmithKline Plc - Key customers
  • Exhibit 79: Pfizer Inc. - Vendor overview
  • Exhibit 80: Pfizer Inc. - Business segments
  • Exhibit 81: Pfizer Inc. - Organizational developments
  • Exhibit 82: Pfizer Inc. - Geographic focus
  • Exhibit 83: Pfizer Inc. - Segment focus
  • Exhibit 84: Pfizer Inc. - Key offerings
  • Exhibit 85: Pfizer Inc. - Key customers
  • Exhibit 86: Validation techniques employed for market sizing
  • Exhibit 87: Definition of market positioning of vendors
Back to Top